全文获取类型
收费全文 | 406916篇 |
免费 | 26717篇 |
国内免费 | 4913篇 |
专业分类
耳鼻咽喉 | 5379篇 |
儿科学 | 8578篇 |
妇产科学 | 10382篇 |
基础医学 | 56226篇 |
口腔科学 | 12259篇 |
临床医学 | 33855篇 |
内科学 | 82461篇 |
皮肤病学 | 8778篇 |
神经病学 | 28512篇 |
特种医学 | 15140篇 |
外国民族医学 | 94篇 |
外科学 | 63711篇 |
综合类 | 14645篇 |
现状与发展 | 7篇 |
一般理论 | 67篇 |
预防医学 | 19261篇 |
眼科学 | 10098篇 |
药学 | 33962篇 |
28篇 | |
中国医学 | 3758篇 |
肿瘤学 | 31345篇 |
出版年
2021年 | 3950篇 |
2020年 | 2651篇 |
2019年 | 3635篇 |
2018年 | 5434篇 |
2017年 | 4319篇 |
2016年 | 4400篇 |
2015年 | 5282篇 |
2014年 | 7225篇 |
2013年 | 8781篇 |
2012年 | 11878篇 |
2011年 | 12427篇 |
2010年 | 7619篇 |
2009年 | 6955篇 |
2008年 | 10868篇 |
2007年 | 11775篇 |
2006年 | 11655篇 |
2005年 | 10690篇 |
2004年 | 9856篇 |
2003年 | 9623篇 |
2002年 | 9172篇 |
2001年 | 28999篇 |
2000年 | 29460篇 |
1999年 | 24316篇 |
1998年 | 5560篇 |
1997年 | 4725篇 |
1996年 | 4154篇 |
1995年 | 3766篇 |
1994年 | 3325篇 |
1993年 | 3021篇 |
1992年 | 16227篇 |
1991年 | 14989篇 |
1990年 | 14295篇 |
1989年 | 14087篇 |
1988年 | 12679篇 |
1987年 | 12165篇 |
1986年 | 11183篇 |
1985年 | 10373篇 |
1984年 | 6943篇 |
1983年 | 5617篇 |
1982年 | 2726篇 |
1979年 | 5514篇 |
1978年 | 3369篇 |
1977年 | 2978篇 |
1975年 | 2653篇 |
1974年 | 3078篇 |
1973年 | 2875篇 |
1972年 | 2835篇 |
1971年 | 2775篇 |
1970年 | 2512篇 |
1969年 | 2547篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
4.
5.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs. 相似文献
6.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
7.
8.
9.
10.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文